Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777182 | 0.81 | MYC (0.38) | CYP1A2CYP2D6CYP2C9GRM1HSD17B10 | |
| SCHEMBL17256744 | 0.77 | RBBP9 (0.35) | ALDH1A1CYP1A2CYP2D6CYP2C9GRM1 | |
| SCHEMBL17256745 | 0.77 | RBBP9 (0.35) | ALDH1A1CYP1A2CYP2D6CYP2C9GRM1 | |
| SCHEMBL17257490 | 0.74 | HSD17B10 (0.34) | HSD17B10MAPT | |
| SCHEMBL17257489 | 0.74 | HSD17B10 (0.34) | HSD17B10MAPT | |
| SCHEMBL689854 | 0.73 | L3MBTL1 (0.56) | CYP1A2CYP2D6CYP2C9GRM1HSD17B10 | |
| SCHEMBL27045168 | 0.73 | ALDH1A1 (0.35) | ALDH1A1HSD17B10KDM4ESMN1; SMN2MAPT | |
| SCHEMBL17257573 | 0.72 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL1706430 | 0.71 | — | — | |
| SCHEMBL1669191 | 0.71 | KDM1A (0.49) | ALDH1A1KDM1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143055-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | Bridgestone Corporation (JP) | 2017-03-22 | — | — | EP | disclosed |
| WO-2015175280-A2 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP | BRIDGESTONE CORPORATION (JP) | 2015-11-19 | — | — | WO | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | ALDH1A1 1373/4885CYP1A2 1383/4885CYP2D6 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.